Department of Neurology, Université de Sherbrooke, Qc, Canada.
Department of Neurosurgery, Université de Sherbrooke, Qc, Canada.
Neurosurgery. 2023 Aug 1;93(2):453-461. doi: 10.1227/neu.0000000000002440. Epub 2023 Mar 2.
The efficacy of stereotactic radiosurgery (SRS) for the relief of trigeminal neuralgia (TN) is well established. Much less is known, however, about the benefit of SRS for multiple sclerosis (MS)-related TN (MS-TN).
To compare outcomes in patients who underwent SRS for MS-TN vs classical/idiopathic TN and identify relative risk factors for failure.
We conducted a retrospective, case-control study of patients who underwent Gamma Knife radiosurgery at our center for MS-TN between October 2004 and November 2017. Cases were matched 1:1 to controls using a propensity score predicting MS probability using pretreatment variables. The final cohort consisted of 154 patients (77 cases and 77 controls). Baseline demographics, pain characteristics, and MRI features were collected before treatment. Pain evolution and complications were obtained at follow-up. Outcomes were analyzed using the Kaplan-Meir estimator and Cox regressions.
There was no statistically significant difference between both groups with regards to initial pain relief (modified Barrow National Institute IIIa or less), which was achieved in 77% of patients with MS and 69% of controls. In responders, 78% of patients with MS and 52% of controls eventually had recurrence. Pain recurred earlier in patients with MS (29 months) than in controls (75 months). Complications were similarly distributed in each group and consisted, in the MS group, of 3% of new bothersome facial hypoesthesia and 1% of new dysesthesia.
SRS is a safe and effective modality to achieve pain freedom in MS-TN. However, pain relief is significantly less durable than in matched controls without MS.
立体定向放射外科(SRS)治疗三叉神经痛(TN)的疗效已得到充分证实。然而,对于多发性硬化症(MS)相关 TN(MS-TN),SRS 的益处却知之甚少。
比较 SRS 治疗 MS-TN 与经典/特发性 TN 的结果,并确定失败的相对危险因素。
我们对 2004 年 10 月至 2017 年 11 月期间在我们中心接受伽玛刀放射外科治疗 MS-TN 的患者进行了回顾性病例对照研究。使用预测治疗前变量中 MS 概率的倾向评分对病例进行 1:1 匹配对照。最终队列包括 154 例患者(77 例病例和 77 例对照)。收集治疗前的基线人口统计学、疼痛特征和 MRI 特征。在随访时获得疼痛演变和并发症。使用 Kaplan-Meier 估计器和 Cox 回归分析结果。
两组患者在初始疼痛缓解(改良 Barrow 国立研究所 IIIa 或以下)方面没有统计学上的显著差异,77%的 MS 患者和 69%的对照组患者达到了这一目标。在有反应的患者中,78%的 MS 患者和 52%的对照组患者最终复发。MS 患者的疼痛复发较早(29 个月),而对照组为 75 个月。并发症在两组中的分布相似,MS 组有 3%的新出现的面部感觉减退和 1%的新出现的感觉异常。
SRS 是一种安全有效的治疗 MS-TN 的方法,可以实现疼痛缓解。然而,缓解效果的持久性明显低于无 MS 的匹配对照组。